Ishita Drugs — 360° view

Ishita Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹3.03 crore and net profit of ₹0.16 crore for the September 2026 quarter.

Ishita Drugs (BSE: ISHITADR) closed at ₹74.01 on 20 Nov 2026, up 5.7% over the past year. Its market capitalisation is ₹22 crore and it trades at 30.3 times earnings.

Share price
₹74.01 (20 Nov 2026)
Market cap
₹22 Cr (20 Nov 2026)
P/E
30.32 (20 Nov 2026)
Revenue
₹3 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
8.66% (FY26)
ROE
6.98% (FY26)
Book value
₹40.0 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹90.85 / ₹66.00 (20 Nov 2026)
1-year return
5.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: ISHITADR

Incorporated in 1992, Ishita Drugs & Industries Ltd is engaged in the manufacturing of various APIs and drug intermediates

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.